Our promise to you:
Guaranteed product quality, expert customer support.
Cas13 is a novel CRISPR effector protein that targets single-stranded RNA. This represents Cas13 as a potentially safe alternative to Cas9, as it induces a loss of functional phenotype without genomic changes.
Unlike most CRISPR systems that target dsDNA, Cas13 has two advanced eukaryotic and prokaryotic nucleotide-binding (HEPN) domains in tandem single-stranded RNA (ssRNA). And Cas13 has two different RNA nuclease activities:
Figure 1: CRISPR-Cas13 targets ssRNA with its crRNA, and the twin HEPN nuclease domains cleaves the sequence non-specifically after the first crRNA guided cleavage at the binding site, leaving blunt ends. (Fernando Perez Rojo. 2018)
CRISPR/Cas9 PlatformCB provides customized CRISPR/Cas13 related services to support a wide range of genomic engineering applications. We can help you flexibly apply the CRISPR/Cas13 system for RNA group editing, RNA imaging in living cells, human disease gene therapy research, and the development of more potential applications for Cas13 system. With the help of an experienced team of experts and a professional technology platform, we provide customers with high-quality crRNA design and synthesis, CRISPR/Cas13 vector packaging, and dCas13 fusion protein production systems.
Our CRISPR/Cas13 genome editing services include but are not limited to
Based on the gene ID you provided, we will design and synthesize at least three crRNA sequences to improve the stability of crRNA in target cells and further improve target editing performance.
➢ Provide non-targeted negative control crRNA in human, mouse and rat genomes (optional)
➢ We provide a variety of vector designs, including crRNA only, crRNA-Cas13.
➢ TET-induced or stably expressed CRISPR/Cas13 construct.
➢ Various vectors, including non-viral and viral vectors (Lentivirus, Adenovirus, AVV).
➢ Viral vectors have the ability to transfect a variety of cells, including cells that are difficult to transfect, such as stem cells, primary cells, suspension cells, etc.
➢ Non-catalytically active PspCas13b is fused to the ADAR2 deaminase domain and can be used for A to I (G) replacement of reporter genes (REPAIR).
CRISPR/Cas9 PlatformCB provides the most effective and reliable services to best meet your needs and promote the development of biomedical and genetic engineering technologies.
Our characteristics and advantages
CRISPR/Cas9 PlatformCB provides comprehensive services in the entire value chain of CRISPR system applications and technology development. Through a consulting, flexible, integrated and interdisciplinary approach, we provide advice, answers, and services to promote your project research. If you have any questions and requirements, please feel free to contact us.
Fernando Perez Rojo. et al. CRISPR-Cas systems: ushering in the new genome editing era. Bioengineered. 2018; 9(1):214–221.